Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNF alpha used for the treatment of IBD: Results from the VERNE study
Por:
Batista, G, Marin-Jimenez, I, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aparicio, J, Aguas, M, Santos-Fernandez, J, Bosca-Watts, MM, Ferreiro-Iglesias, R, Merino, O, Aldeguer, X, Corttes, X, Sicilia, B, Mesonero, F, Barreiro-de Acosta, M
Publicada:
1 ene 2022
Ahead of Print:
1 dic 2021
Resumen:
Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs.
Aims: To assess the treatment patterns with the first anti-TNF alpha in IBD.
Methods: Retrospective, observational study.
Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC.
Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNF alpha due to inappropriate disease control. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
Filiaciones:
Batista, G:
Hosp La Fe, Dept Gastroenterol, Valencia, Spain
Marin-Jimenez, I:
Hosp Gregorio Maranon, Dept Gastroenterol, Madrid, Spain
Inst Invest Sanitaria Gregorio Maranon IISGM, Madrid, Spain
Fores, A:
Hosp Gen Univ Castellon, Castellon de La Plana, Spain
Garcia-Planella, E:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Arguelles-Arias, F:
Hosp Univ Virgen Macarena, Seville, Spain
Tagarro, I:
Takeda Farmaceut Espana SA, Madrid, Spain
Fernandez-Nistal, A:
Takeda Farmaceut Espana SA, Madrid, Spain
Montoto, C:
Takeda Farmaceut Espana SA, Madrid, Spain
Aparicio, J:
Takeda Farmaceut Espana SA, Madrid, Spain
Aguas, M:
Hosp La Fe, Dept Gastroenterol, Valencia, Spain
Santos-Fernandez, J:
Hosp Univ Rio Hortega, Dept Gastroenterol, Valladolid, Spain
Bosca-Watts, MM:
Univ Clin Hosp Valencia, Dept Gastroenterol, IBD Unit, Valencia, Spain
Ferreiro-Iglesias, R:
Hosp Clin Univ Santiago, Dept Gastroenterol, Santiago De Compostela, Spain
Merino, O:
Hosp Univ Cruces, Dept Gastroenterol, Bilbao, Spain
Aldeguer, X:
Hosp Dr Josep Trueta, Dept Gastroenterol, Girona, Spain
Corttes, X:
Internal Med Hosp Sagunto, Gastroenterol Sect, IBD Unit, Sagunto, Spain
Univ Cardenal Herrera CEU, Castellon de La Plana, Spain
Sicilia, B:
Hosp Univ Burgos, Burgos, Spain
Mesonero, F:
Hosp Ramon & Cajal, Dept Gastroenterol, Madrid, Spain
Barreiro-de Acosta, M:
Hosp Clin Univ Santiago, Dept Gastroenterol, Santiago De Compostela, Spain
hybrid
|